Physician profile
Ryan A Carpenter
NPI 1639431927
$8,231.76
in general payments reported to CMS, 2019-2025
40 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,622 · 2022: $1,234 · 2023: $1,654 · 2024: $1,926 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,375.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.68 | 2021-2025 | |
| Novo Nordisk INC | $1,035.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $607.80 | 2021-2025 | |
| Gilead Sciences, INC. | $567.28 | 2021-2025 | |
| Lilly USA, LLC | $452.77 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $359.51 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.81 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $330.79 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.80 | 2021-2023 | Jardiance |
| Amgen INC. | $277.78 | 2021-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $236.59 | 2021-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $186.51 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $183.03 | 2021-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $152.71 | 2021-2023 | Austedo Xr, Austedo |
| Alkermes, INC. | $129.36 | 2022-2024 | Vivitrol, Vivitrol |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.